Facility will manufacture materials that are vital to production of plasmid-based therapies and vaccines

High-resolution images of nanoparticles and beam-sensitive materials can now be obtained from a commercially available desktop SEM

1,200+ products to be identified for environmentally friendly capabilities and sustainability objectives

Strategic investments over the last two years expand global capabilities to support advanced therapies and large molecule development and manufacturing